Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy

Figures & data

Figure 1 The areas to measure the macular sensitivity: center (foveal threshold), four points (blue line), 16 points (red line), and 36 points (green line) from fixation point.

Figure 2 The areas to measure the macular sensitivity: superotemporal, superonasal, inferotemporal, and inferotemporal from fixation point.

Table 1 Demographic and clinical characteristics of the patients (n=24)

Characteristics	Data
Demographic data
Age (median, min–max) years	46, 36–68
Sex: male/female	17/7
Laterality: right eye/left eye	15/9
Education above high school (number of patients)	7
Clinical characteristics
Duration before PDT (median, min–max) weeks	32, 15–96
Duration after PDT (median, min–max) weeks	126, 48–216
site of leakage: subfoveal leakage	2
Juxtafoveal leakage	19
Extrafoveal leakage	3
Spot size (median, min–max) µm	2,216, 1,089–4,398

Abbreviations: PDT, photodynamic therapy; min, minimum; max, maximum.

Table 2 The comparative mean macular sensitivities in study and control eyes: four lines; foveal threshold, four, 16, and 36 points from fixation and four areas; superotemporal, superonasal, inferotemporal, and inferonasal areas

Study areas	Mean macular sensitivity		P-value
	Study eyes (decibel)	Control eyes (decibel)
Center: foveal threshold	28.75±6.52	32.33±3.35	<0.001
Blue line, four points	29.27±3.33	30.92±1.49	<0.001
Red line, 16 points	29.28±3.34	31.02±1.67	<0.001
Green line, 36 points	28.85±3.22	30.67±1.65	<0.001
Superotemporal area	28.56±3.01	30.43±1.15	<0.001
Superonasal area	28.23±3.18	30.22±1.21	<0.001
Inferotemporal area	29.11±2.86	30.81 ± 1.49	<0.001
Inferonasal area	29.35±2.02	30.44± 1.49	0.002

Note: Data presented as mean ± SD.